By L. Hanson. Texas Tech University.
The depleted the reservoir or could myeloablative chemotherapy ablate pilot trial treated 4 relapsed HIV-1-positive NHL patients with the infected lymphocyte pool? To address this sildenafil 25mg overnight delivery, Cillo et al32 reported hematopoietic cells transduced with a lentivirus encoding 3 anti- HIV-1 RNAs 25mg sildenafil sale, namely TAR, siRNA to tat/rev, and a ribozyme a retrospective analysis of frozen PBMC specimens from AIDS 37 targeting CCR5. The cells were infused in combination with lymphoma HCT recipients who remained on ART during much of unmodiﬁed cells after high-dose CBV therapy. Patients had no detectable HIV-1 RNA in the plasma at serious adverse events associated with the genetically modiﬁed variable time points after HCT. Specimens from blood, studied 36 cells, but, similar to the aforementioned Mitsuyasu study, levels of before HCT and at one other post-HCT time, used assays for HIV gene marking, although present in all patients in the peripheral RNA and DNA having single-copy sensitivity, a surrogate measure blood, were low at 0. No HIV-1 RNA was detected in plasma by due in part to competition with the much higher levels of unmodi- routine assays, but with the more sensitive assay, 9 of 10 patients ﬁed hematopoietic cells that were infused concomitantly with the were viremic after HCT while on ART, with a range of 0. HIV-1 gene copies/mL, and 9/10 were found to have detectable HIV-1 DNA. This ﬁnding may have been due to 2 factors: (1) the The evolving paradigm is that success is contingent upon high levels autologous graft likely had infectious virus in contaminating T-cells of only genetically modiﬁed hematopoietic cells being infused or and (2) the endogenous reservoir was still present despite the selection of the protected cells after engraftment. Ultimately, the test cytoreductive conditioning regimen. Patients in cohort 1 (n 6) underwent a 12-week ATI of ART beginning 4 weeks after the T-cell infusion. HIV-1 viral load was undetectable at the start of ATI and became detectable in 4 of the 6 patients at 2-4 weeks after cessation of c-ART. There was a decline of CD4 counts during ATI, but this decline in CCR5-modiﬁed cells (1. Only one serious adverse event was associated with the cell infusion and was attributed to a transfusion reaction. Level of gene marking expressed as number of copies of trial has thus successfully set the platform for ZFN editing of cells as vector (WPRE) per 100 blood cells analyzed over time. Unique a viable and well-tolerated approach that may lead to in vivo patient identiﬁers are listed in the upper right corner of the graph. Limits resistance of these CCR5-edited cells to HIV-1. The future trial of of quantiﬁcation (stippled) and limits of detection (diagonal lines) values ZFN-1-modiﬁed hematopoietic cells in conjunction with nonmyelo- were determined for each ampliﬁcation reaction and typically were in the ablative busulfan conditioning in selected HIV-1-positive patients range of 0. We have adopted a stepwise approach, with Conﬂict-of-interest disclosures: A. In addition, infusion of only genetically modiﬁed hematopoi- etic Cell Transplantation, Beckman Research Institute, City of Hope etic cells could be justiﬁed in the nonmyeloablative setting because Medical Center, 1500 E Duarte Road, Duarte, CA 91010. Phone: early or late graft failure in this setting would not have the same 626-359-8111; Fax: 626-301-8973; e-mail: AKrishnan@coh. A pilot trial using busulfan at nonmyeloablative doses in ﬁrst-remission HIV-1- References positive NHL patients is open at City of Hope (www. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin’s lym- gov identiﬁer #NCT01961063). Busulfan is not considered an antilymphoma therapy, so its use in 2. Primary effusion lym- the current trial is solely to facilitate engraftment. Clinical trials in phoma: a distinct clinicopathologic entity associated with the Kaposi’s human genetic diseases, especially in pediatric populations, using sarcoma-associated herpes virus. Sullivan RJ, Pantanowitz L, Casper C, Stebbing J, Dezube BJ. Candotti et al39 correlated busulfan HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi dosing with area under the curve (AUC) measurements demonstrat- sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effu- 2 sion lymphoma, and multicentric Castleman disease. Emerging targets and novel strategies associated with engraftment. Toxicity was mild, with transient in the treatment of AIDS-related Kaposi’s sarcoma: bidirectional neutropenia, mild thrombocytopenia, and transient elevated liver translational science. The ultimate step for the HIV-1 trials is to use this 5. Distinct subsets of primary busulfan-based conditioning in HIV-1-infected patients without effusion lymphoma can be identiﬁed based on their cellular gene malignancy. Such a trial is planned at City of Hope and will use expression proﬁle and viral association. AUC-targeted busulfan dosing, followed by infusion of a CCR5- 6. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in negative product edited by a zinc ﬁnger nuclease (ZFN).
Biol Blood Marrow Trans- lapsed or refractory acute myeloid leukemia irrespective of plant 25mg sildenafil visa. Final results of a phase 2 hematopoietic stem cell transplantation for acute myeloid open-label order 100mg sildenafil with visa, monotherapy efﬁcacy and safety study of quizar- leukemia patients with internal tandem duplication of FLT3. Impact of FLT3 internal chemotherapy or hematopoietic stem cell transplantation [ab- tandem duplication on the outcome of related and unrelated stract]. FLT3/ITD AML and the law of unintended conse- tinib (AC220) in patients 60 years of age with FLT3 ITD quences. I clinical study demonstrates inhibition of FLT3 phosphoryla- 53. Azacitidine tion by SU11248 in acute myeloid leukemia patients. Clin prolongs overall survival compared with conventional care Cancer Res. Ponatinib in patients older patients with acute myeloid leukemia. High activity of azacytidine plus sorafenib in patients with acute myeloid sorafenib in FLT3-ITD-positive acute myeloid leukemia syner- leukemia and FLT-3 internal tandem duplication mutation. Sorafenib treatment of leukemia: a review of their efﬁcacy and mechanisms of FLT3-ITD acute myeloid leukemia: favorable initial outcome resistance. The disease represents a range of quantitative and qualitative pathologies of the adhesive glycoprotein von Willebrand factor (VWF). The pathogenic mechanisms responsible for the type 2 qualitative variants of VWF are now well characterized, with most mutations representing missense substitutions inﬂuencing VWF multimer structure and interactions with platelet GPIb and collagen and with factor VIII. The molecular pathology of type 3 VWD has been similarly well characterized, with an array of different mutation types producing either a null phenotype or the production of VWF that is not secreted. In contrast, the pathogenetic mechanisms responsible for type 1 VWD remain only partially resolved. In the hemostasis laboratory, the measurement of VWF:Ag and VWF:RCo are key components in the diagnostic algorithm for VWD, although the introduction of direct GPIb -binding assays may become the functional assay of choice. Molecular genetic testing can provide additional beneﬁt, but its utility is currently limited to type 2 and 3 VWD. The treatment of bleeding in VWD involves the use of desmopressin and plasma-derived VWF concentrates and a variety of adjunctive agents. Finally, a new recombinant VWF concentrate has just completed clinical trial evaluation and has demonstrated excellent hemostatic efﬁcacy and safety. Introduction The VWF gene and protein Our knowledge of von Willebrand disease (VWD) pathogenesis and The 175-kb VWF gene is located on the short arm of chromosome the subsequent application of this information to beneﬁt VWD 12 and comprises 52 exons. The VWF gene sequence is replicated in diagnosis and therapy has advanced substantially over the past 25 part by a partial VWF pseudogene on chromosome 22. After the immunologic distinction between von Willebrand evolutionary remnant recapitulates exons 23-34 of the VWF gene factor (VWF) and factor VIII (FVIII) in the 1970s, the gene for with 3% variance, a fact that signiﬁcantly complicates the genetic VWF was cloned by 4 groups in 1985,1-4 and thus began an era of analysis of this central region of the VWF gene. The 9-kb VWF transcript encodes a pre-pro-VWF protein of 2813 amino acids. The protein undergoes extensive posttranslational modiﬁ- cations, including the removal of leader and propeptide sequences, VWD epidemiology and classiﬁcation dimer and eventual multimer generation, and the addition of many VWD is the most common autosomally inherited bleeding disorder, N-linked and O-linked carbohydrate structures. A recently revised resulting in signiﬁcant bleeding symptoms in 1 in 1000 subjects,5 annotation of the VWF protein structure indicates that whereas the although prevalence estimates ranging from 1%6 to1in100007 platelet- and collagen-binding A domains of the protein form globular- have also been reported in the literature. The disease shows no like structures, a series of repetitive VWC domains toward the geographical or ethnic predilection, but although both sexes inherit C-terminus provide the protein with increased length and ﬂexibility, mutant VWF alleles with equal frequency, females outnumber males thus facilitating the transition between compact and extended conforma- tions under conditions of shear stress in the vasculature (Figure 1). Pathogenesis of VWD Over the past 25 years, signiﬁcant progress has been made in our The classiﬁcation of VWD has remained relatively unchanged for knowledge of the molecular pathogenesis of VWD, with particu- the past decade. The key hemostatic test This article was selected by the Blood and Hematology 2013 American Society of Hematology Education Program editors for concurrent submission to Blood and Hematology 2013. This article is reprinted with permission from Blood. VWD classiﬁcation and pathogenetic mechanisms ristocetin-induced platelet agglutination test that shows a lack of response in type 2A disease and hyperresponsiveness in 2B VWD. VWD subtype Pathogenetic mechanisms The lack of HMWMs in type 2A disease is due to a range of Type 1 VWD ● 65% of index cases have candidate biosynthetic and post-biosynthetic abnormalities that inﬂuence the VWF mutations generation and proteolysis of the protein. The phenotype is ● Enhanced ADAMTS13 proteolysis transmitted as a highly penetrant dominant trait, and clinical and Type 2B VWD ● Missense variants in A1 domain mouse model evidence indicates that the bleeding severity and ● Enhanced binding to GPIb Type 2M VWD ● Missense variants in A1 and A3 accompanying thrombocytopenia is related predominantly to the speciﬁc type 2B mutation inherited. The GPIb - molecular-weight multimers (HMWMs) and sometimes intermedi- binding mutants demonstrate reduced VWF:RCo/VWF:Ag ratios of ate-molecular-weight multimers. The GPIb -binding substitutions are lo- cated in the A1 domain and collagen-binding variants have been identiﬁed in the A3 domain and, more recently, in the A1 domain. Although the “classical” type 2M phenotype associated with poor GPIb binding and unresponsiveness to desmopressin is well recognized, the status of the collagen-binding mutants remains less clear. Earlier reports of poor binding to type I and III collagens were associated with missense substitutions in the A3 domain,16,17 but recent evidence suggests that substitutions in the A1 domain may impede binding to type VI collagen and also result in a mild bleeding phenotype. In contrast to the other type 2 variants of VWD, type 2N disease is transmitted in a recessive fashion with a variety of homozygous and compound heterozygous genotypes, resulting in FVIII levels between 5% and 40%. Diagram representing the revised annotation of the VWF mature subunit structure.
The use of rescue medications (days/week) decreased with both active treatments (levalbuterol compared with placebo generic 100 mg sildenafil, P<0 buy 100 mg sildenafil with mastercard. These trials all took place in the emergency department and were similarly designed randomized controlled trials, with blinding of the patient and treating physician. Ten patients were excluded from analysis, including 6 due to protocol violation. The authors noted no differences in the secondary outcomes of percent of patients hospitalized from the emergency department, length of care in the emergency department, median number of nebulizations, or rate of adverse events. In the levalbuterol group 11% of patients were hospitalized; in the albuterol group the rate was 13%. The authors indicate that their study was underpowered to detect a possible difference in rates between groups. In contrast to the 2 studies just discussed, a significant decrease in hospital admission rate was noted with the use of levalbuterol in the emergency department in a study by Carl and 46 associates. This study (N=547) of predominantly African American boys with moderate to severe chronic asthma randomized children aged 1 to 18 years upon presentation to the emergency department. Patients received nebulized treatment at 20-minute intervals of 1. The average hospital admission rate for the last 5 years was 42% for this study setting, and this study was powered to examine hospital admission rates as a primary outcome. The use of albuterol in the 24 hours prior to the emergency department visit correlated with hospital admissions (P=0. After controlling for age, treatment with >3 aerosols in the last 12 hours and oral corticosteroid use in the previous 24 hours, investigators found that levalbuterol was still associated with a lower admission rate, 43% compared with 53% for albuterol (relative risk 1. Exercise-induced asthma No studies compared albuterol with levalbuterol in persons with exercise-induced asthma. Levalbuterol compared with albuterol plus ipratropium bromide Adult asthma No studies reported this combination of drugs. Pediatric asthma 88 Ralston and colleagues compared levalbuterol to the combination of racemic albuterol plus ipratropium bromide in 140 children age 6 to 18 years seen in the emergency department with acute asthma in a fair-quality study. For the studys primary outcome of length of stay in the emergency department or the hospital (if admitted), the median value was comparable between the 2 study groups (P=0. The groups were also comparable for the number of nebulization treatments in the emergency department and the time between treatments. Fewer patients were given adjunct medications (including steroids) in the levalbuterol group than in the albuterol- plus-ipratropium bromide group (P=0. Albuterol compared with albuterol plus ipratropium bromide Adult asthma 12 The Cochrane systematic review by Westby and colleagues was used as the basis for this drug comparison. This review examined the effectiveness of anticholinergic agents compared with placebo and compared with beta -agonists, or as adjuncts to beta -agonists. These authors2 2 searched multiple bibliographic databases up to August 2004 and identified 9 studies with follow-up greater than 24 hours involving 440 patients in comparing anticholinergic drug plus beta -agonist combination therapy with beta -agonist monotherapy. One of the studies examined2 2 CR terbutaline and 2 other studies did not provide sufficient data for inclusion in the reviewers meta-analysis. These reviewers noted heterogeneity across the remaining studies for follow-up intervals, dosing, and study design (parallel and crossover). They found no significant difference in any of the symptom scores between treatments. Overall there were fewer withdrawals with beta -agonist monotherapy. Two studies looked at the number of patients with exacerbations and2 found no significant differences between treatments. There was also little difference in adverse effects between the 2 treatments. In a good- quality trial of adults (89% African American) presenting to an emergency department with 84 acute asthma, Salo and colleagues randomized 66 patients to either albuterol 7. There was no significant difference in hospital admission rates between the combination therapy (25%) and albuterol monotherapy groups (16. The odds ratio for hospital admissions in the combination group was 1. Quick-relief medications for asthma Page 20 of 113 Final Report Update 1 Drug Effectiveness Review Project Pediatric asthma 9 The Cochrane review by McDonald and colleagues included studies of children using an anticholinergic drug for more than 1 week. One very small trial compared ipratropium bromide plus salbutamol with placebo plus salbutamol, both delivered by metered aerosol 4 times daily. A second trial compared ipratropium bromide plus fenoterol with placebo plus fenoterol delivered via nebulizer 3 times daily. Both trials failed to show any significant benefit with respect to symptom scores from the addition of anticholinergic drugs to beta -agonist monotherapy. In a fair-quality trial set in India, children age 5 to 15 years with mild to moderate acute exacerbation of asthma were randomized to either 4 actuations of ipratropium bromide (80 µg total) or placebo given with a metered dose inhaler using a spacer. All children were first given 4 actuations of salbutamol (400 mcg total) via a metered dose inhaler and spacer, then the study drug. Thirty minutes after treatment there was no significant difference between treatments in scores for wheezing or for use of accessory muscles.
An open randomised cross- over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens order sildenafil 25 mg with mastercard. Ondansetron (OND) vs granisetron (GRA) in the control of chemotherapy induced acute emesis: A multicentric randomized trial buy 100 mg sildenafil otc. Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy. Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L. Herrington JD, Kwan P, Young RR, Lagow E, Lagrone L, Riggs MW. Randomized, multicenter comparison of oral granisetron and oral ondansetron for emetogenic chemotherapy. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Antiemetics Page 47 of 136 Final Report Update 1 Drug Effectiveness Review Project 32. Tropisetron, ondansetron, and granisetron for control of chemotherapy- induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost. Randomised double blind crossover study comparing ondansetron, granisetron and tropisetron. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Fox-Geiman MP, Fisher SG, Kiley K, Fletcher-Gonzalez D, Porter N, Stiff P. Double- blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation. Ondansetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting: Results of a prospective randomized trial. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: A randomized controlled trial. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. Noble A, Bremer K, Goedhals L, Cupissol D, Dilly SG. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: assessment of efficacy, safety and patient preference. Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: A multicenter, double-blind, randomized parallel study. Antiemetics Page 48 of 136 Final Report Update 1 Drug Effectiveness Review Project 45. Comparison of antiemetic efficacy of granisetron and ondansetron in Oriental patients: A randomized crossover study. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma. A comparison of oral ondansetron and intravenous granisetron for the prevention of nausea and emesis associated with cisplatin- based chemotherapy. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: A multicentre, double- blind, double-dummy, randomised, parallel-group study. Yalcin S, Tekuzman G, Baltali E, Ozisik Y, Barista I. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: A randomized study. American Journal of Clinical Oncology: Cancer Clinical Trials. Zeidman A, Dayan DB, Zion TB, Kaufman O, Cohen AM, Mittelman M. Granisetron and ondansetron for chemotherapy-related nausea and vomiting.